Our Goal: Develop universal-RAS/RAF medicines with broad activity for large populations of cancer patients.

Our lead clinical stage candidate IMM-1-104 aims for activity against tumors driven by mutations in RAS and beyond.

Immuneering’s lead product candidate IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through Deep Cyclic Inhibition of the MAPK pathway with once-daily oral dosing. IMM-1-104 is currently being evaluated in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a Deep Cyclic Inhibitor with twice-daily oral dosing, currently being evaluated in patients with advanced solid tumors harboring RAF or RAS mutations, as well as several early-stage programs.


Immuneering is advancing a robust pipeline of novel drug programs starting with IMM-1-104, which is designed to achieve activity in tumors with mutations in RAS and beyond through deep, cyclic inhibition. This differentiated approach aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, basal level of signaling designed to spare healthy cells.


Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data in new and creative ways providing counterintuitive insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views.